Precision Health Diagnostic and Surveillance Network uses S Gene Target Failure (SGTF) combined with sequencing technologies to identify emerging SARS-CoV-2 variants

Introduction

The coronavirus disease 2019 (COVID-19), an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the first global pandemic of the 21^st century. Several genomic epidemiology tools have been developed to track the public and population health impact of SARS-CoV-2 community spread worldwide [1-5]. More than 137 million cases and close to 3 million deaths have been reported since the beginning of the pandemic in January 2020 (https://coronavirus.jhu.edu). A SARS-CoV-2 Variant of Concern (VOC), known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7, was detected in the United Kingdom in November 2020 and has now spread to multiple countries worldwide [6-8]. Genomic epidemiology studies reveal B.1.1.7 possesses many non-synonymous substitutions of biological/immunological significance, in particular Spike mutations HVΔ69-70, N501Y and P681H, as well as ORF8 Q27stop and ORF7a [7, 9, 10]. B.1.1.7 shows increased transmissibility and has rapidly become the dominant VOC in the United States (US) (https://covid.cdc.gov) [11-14].

The HVΔ69-70 mutation is a deletion in the SARS-CoV-2 21765-21770 genome region that removes Spike amino acids 69 and 70. The HVΔ69-70 causes target failure in the TaqPath COVID-19 RT-PCR Combo Kit (ThermoFisher) assay, catalog number A47814 (TaqPath)[15]. TaqPath is designed to co-amplify sections of three SARS-CoV-2 viral genes: Nucleocapsid (N); Open Reading Frame 1ab (ORF1ab); and Spike (S) [16]. The Spike HVΔ69/70 deletion prevents the oligonucleotide probe from binding its target sequence, leading to what has been termed S gene dropout or S gene target failure (SGTF) [6]. SGTF is associated with significantly higher viral loads in samples tested by TaqPath[16]. S gene target late amplification (SGTL) has also been observed in a subset of samples having Cycle threshold [17] values for S gene >5 units higher than the maximum Ct value obtained for the other two assay targets: N and ORF1ab.

The US and countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant require immediate and decisive action to minimize COVID-19 morbidity and mortality [14, 18]. However, the US does not have a national genomic epidemiology surveillance network for COVID-19 whole genome sequencing (WGS) program in place. Therefore, only a small fraction of all new cases is being sequenced ad-hoc. SGTF has been shown to correlate with the Δ69-70 mutation highly. Evidently, SGTF can be used as a proxy to monitor SARS-CoV-2 lineage prevalence and geo-temporal distribution and may be near-direct measure of B.1.1.7 [15, 19].

In an urgent response to the SARS-CoV-2 global pandemic, a consortium of researchers and scientists working in academia, industry, and clinical laboratories implemented a Precision Health Diagnostic and Surveillance Network (PHx) in March 2020. PHx’s original objective was to augment SARS-CoV-2 molecular testing capacity and implement a genomic surveillance network in Baltimore, New York and Puerto Rico[20]. The present work describes the development of an evidenced-based genomic surveillance algorithm that combines RT-PCR and sequencing technologies to identify VOCs.

Materials and Methods

Results

TaqPath data from close to 508,969 patients revealed a frequency of SGTF 47% for the last week of March 2021 in both Puerto Rico and US laboratories. The overall frequency of SGTL (15.1%), SGTF (9.2%), and SGTF with N and ORF1ab Cts <28 (2.5%) in Puerto Rico was high from March 2020 through March 2021. SGTF steadily increased exponentially from 4% in November 2020 to 47% in March 2021 in Puerto Rico. The average weekly SGTF rate in US samples was high (>8%) from late December to early January, and then also increased exponentially through April (48%) (Figure 1). During January 2021 47% of the SGTF samples were identified as B.1.1.7. when sequenced. In February, most (90%) of the sequenced samples were B.1.1.7, including 100% (147/147) from February 15-23[15].

• Download figure
• Open in new tab

Figure 1.

Frequency of S Gene Target Failure (SGTF) in samples from Connecticut, Illinois, New Jersey, New York, and Puerto Rico

A subset of samples (n=100) with SGTF (74%) or high viral load in S (<28) were evaluated with Sanger sequencing (Supplemental Table 1). Most samples (97%) had a Spike mutation: Δ69/70 (91%), N501Y (91%) and 82% had both Δ69/70 and N501Y. A majority of the samples (58%) with S <28 had the E484K mutation> E484K, a mutation located in the RBD region, is seen in SARS-CoV-2 B.1.351, P.1, P.2 and R.1 lineages[23].

The rise of SGFT in Puerto Rico is concurrent with a sharp increase in COVID-19 variants identified among viral sequences from Puerto Rico uploaded to GISAID (Figure 2), as of April 18, 2021 (n= 461). Viral sequences from Puerto Rico are classified under 52 different lineages and six clades Most samples were from nasopharyngeal specimens (73.9%) and are classified under seven distinct lineages: B.1.1.7 (27.7%%); B.1.588 (18.8%), B.1 (10%), B.1.2 (9.7%); B.1.1.225 (6.9%), B.1.426 (6.9%), and B.1.1 (6.4%) and four Clades: GH (49.7%); GR (21.5%); G (16.5%) and GRY (11.1%). B.1.1.7 frequency increased from <1% in the last week of January 2021, to 51.5% of viral sequences in the last week of March 2021, to become the dominant VOC In Puerto Rico.

• Download figure
• Open in new tab

Figure 2.

Frequency of SAS-CoV-2 variants in samples from Puerto Rico in GISAID (n=461), by Lineage.

There are 43,202 viral sequences from Connecticut, Illinois, New Jersey, New York and Puerto Rico submitted to GISAID. The median lag-time between sample collection and sample submission dates is 24 days. The lag-time mean is 51 days. The minimum lag-time is 3 days. The average daily lag-time has steadily declined from a mean of 17 days on March 1, 2021 to 14 days on March 31, 2021 (Figure 3).

• Download figure
• Open in new tab

Figure 3.

Mean daily lag time between sample collection and sequencing date from February 2020 through March 31, 2021 in Connecticut, Illinois, New Jersey, New York and Puerto Rico.

Summary statistics and Interquartile Range of ORF1ab, N, S, and MS2 Cycle Threshold (Ct) [17] values for samples from Puerto Rico listed in Table 1, were used to develop a variant identification algorithm (See Supplemental Materials). The commonly used formula to calculate outliers (Q1-(1.5 x IQR) was used to identify an evidence-based Ct cutoff (Ct <28) for a proposed VOC variant identification algorithm (Figure 4).

• Download figure
• Open in new tab

Figure 4.

Variant of Concern Identification algorithm

Samples with SGTF should be sequenced. Samples with Ct values < 28 for N, ORF1ab or E in SARS-CoV-2 clinical samples without S gene data, should be evaluated for the presence of VOCs with Research use Only (ROU) kits that identify specific VOC mutations, as triage before WGS. Patients infected with VOCs should be effectively triaged for isolation, contact tracing and follow-up treatment purposes. Patients with SGTF, or positive PCR results for N501Y or E484K, should be immediately placed into quarantine and a VOC contact tracing protocol needs to be urgently set in motion. According to the proposed VOC identification algorithm, currently 50% of all positive samples in Puerto Rico and the US should be managed as potential B.1.1.7 carriers with VOC quarantine and contact tracing protocols while their lineage is confirmed by WGS in surveillance laboratories..

Discussion

The evidence from four different US States and Puerto Rico suggests that SGTF highly correlates with B.1.1.7 prevalence. The frequency of SGTF in Puerto Rico steadily increased from 4% in November 2020 to 47% in March 2021. Similarly, SGTF in the four US States, which was high (>8%) in early January, increased to 48% in March. Concurrently, B.1.1.7 became the dominant VOC in Puerto Rico and the US in March 2021. Given the exponential rise in SGTF and B.1.1.7 prevalence, a robust VOC genomic surveillance strategy must be quickly implemented. RT-PCR can be used to identify potential VOC carriers. Patients with SGTF should be sequenced to identify viral lineage. Laboratories that do not amplify S can use ROU PCR or Sanger sequencing-based alternatives to identify VOC’s sentinel mutations in samples with E, ORF1ab, or N Ct values <28, as a WGS triage strategy. Patients identified as presumptive carriers of a VOCs, by SGTF or Ct values < 28, should be placed in immediate preventive quarantine until WGS data confirms their variant status.

Given the average current lag time of 15 days between clinical diagnosis and receipt of WGS results, SGTF patients should be immediately placed in quarantine for a minimum of 14 days and until they have a negative PCR test result from a self-collected sample at home. In parallel, around the clock VOC contact tracing efforts should be put in place, to prevent B.1.1.7 greater community spread. According to our evidence-based algorithm, approximately 50% of all positive patients in the four States and Puerto Rico had SGTF in March. These patients should have been placed in preventive quarantine until WGS confirmed their variant status and around the clock VOC contact tracing efforts should have been inmediately put in place.

Genomic epidemiology tools that can quickly identify and track in real-time COVID-19 VOCs improve our understanding of the transmissibility, pathogenicity, morbidity and mortality of each variant detected in geographically defined populations [24, 25]. This approach will enable the deployment of targeted, evidence-based strategies, to quickly screen for COVID-19 VOCs and identify clusters, leading to a decrease in the spread of community transmission. PHx, a critical consortium of researchers and scientists working in academia, industry, and clinical laboratories developed an evidence-based method to screen SARS-CoV-2 positive samples for COVID-19 VOCs. The PPM was a highly effective framework to guide the conceptualization and implementation of PHx. Evaluation frameworks, such as PPM, can improve the understanding of the relationship between complex variables such as community attitudes, knowledge, and screening test utilization and implementation, which determine the uptake of any screening intervention [21, 26]. Given the complexity of behavioral change processes during a global pandemic such as COVID-19, predisposing factors and barriers identified during the implementation of PHx can guide SARS-CoV-2 public policy and funding decision-making. Lessons learned from PHx can inform the urgent deployment of precision health clinical and surveillance networks. During this one year-long period the most important lesson learned is that the business model of clinical laboratories, which operate with very small profit margins, does not have much leeway for collaborative clinical or research efforts.

The main limitations of this study are the lack of established workflows, public policy guidelines and funding streams for the implementation and administration of a genomic surveillance network. The convenience samples and data used for this report was gathered ad-hoc by academic institutions, public and private organizations, as well as state and federal agencies. Data integrity, uniformity and reliability are thus compromised, and should be treated as such. Uniform sample handling and management workflows, needed to assure data reproducibility, are not in place. For example, clinical laboratories discard their samples after diagnosis, which for COVID-19 EUA approved tests, are qualitative decisions based on proprietary algorithms designed by test manufacturers. These closed PCR tests do not require Ct interpretation, nor molecular biology expertise either from the user. In addition, WGS is just entering the clinical and regulatory setting. Therefore, clinical laboratory scientists and Department of Health staff are not usually trained to sequence samples, analyze WGS data, or develop genomic surveillance programs based on RT-PCR or WGS data. The combination of these complex factors, buttressed by sample and data management asymmetry between clinical and sequencing laboratories, as well as state and federal agencies, introduce barriers to sample and data workflows, eventually impinging on results interpretation.

Our results suggest that a genomic surveillance network plays a critical role during the current stage of the COVID-19 pandemic. Patients infected with VOCs should be secured into quarantine immediately and a VOC contact tracing effort should be forcefully implemented to curtail community spread of VOCs. The evidence-based Molecular Epidemiology and Genomic Surveillance algorithm developed by PHx can quickly identify emerging VOCs as a valuable tool for identifying individual carriers of highly infectious variants, who can then be effectively triaged for isolation, contact tracing and treatment purposes.

Resource Availability

Declarations of Interests

M.J.M., R.B., N.B., G.K., J.M., C.E.M., and U.P., work for Tempus Labs. R.G.P. works for LifeGene-Biomarks. All other authors declare no competing interests.